Medicare may save $1.8B from four drugs in first year of price negotiations, research finds
02 Aug 2023
A new paper published this week claims that in 2026, when Medicare negotiations for drug prices kick off, the minimum discount stipulated by the Inflation Reduction Act exceeds 2020 rebates for only four of the 10 drugs to be negotiated.
On Sept. 1, CMS is expected to announce those 10 drugs first subject to government price negotiations.
“These include etanercept (Enbrel), which will be subject to at least a 60% discount, up from an estimated rebate of 39.1%, and the cancer drugs ibrutinib (Imbruvica), palbociclib (Ibrance), and enzalutamide (Xtandi), all of which will be subject to a minimum discount of 25%, up from estimated rebates of 9%, 5.7%, and 15.0%, respectively,” researchers from the University of California, San Diego and Washington, DC’s West Health Policy Center
wrote
in the
Journal of Managed Care & Specialty Pharmacy.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.